nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—Vismodegib—Sulfasalazine—ulcerative colitis	0.413	1	CrCrCtD
Sorafenib—ABCB1—ulcerative colitis	0.0601	1	CbGaD
Sorafenib—ABCC4—Mercaptopurine—ulcerative colitis	0.0293	0.103	CbGbCtD
Sorafenib—ABCC2—Sulfasalazine—ulcerative colitis	0.0142	0.05	CbGbCtD
Sorafenib—ABCG2—Sulfasalazine—ulcerative colitis	0.0128	0.0452	CbGbCtD
Sorafenib—CYP2B6—Nicotine—ulcerative colitis	0.0116	0.0409	CbGbCtD
Sorafenib—CYP2B6—Cholecalciferol—ulcerative colitis	0.0104	0.0367	CbGbCtD
Sorafenib—ABCG2—Hydrocortisone—ulcerative colitis	0.0103	0.0363	CbGbCtD
Sorafenib—CYP2C8—Nicotine—ulcerative colitis	0.00879	0.031	CbGbCtD
Sorafenib—CYP3A4—Budesonide—ulcerative colitis	0.00819	0.0288	CbGbCtD
Sorafenib—RET—enteric nervous system—ulcerative colitis	0.00806	0.146	CbGeAlD
Sorafenib—CYP2C8—Cholecalciferol—ulcerative colitis	0.00788	0.0278	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Hydrocortisone—ulcerative colitis	0.0076	0.0268	CbGbCtD
Sorafenib—CYP3A7—Hydrocortisone—ulcerative colitis	0.0076	0.0268	CbGbCtD
Sorafenib—CYP2C19—Nicotine—ulcerative colitis	0.00737	0.026	CbGbCtD
Sorafenib—CYP3A5—Sulfasalazine—ulcerative colitis	0.00711	0.025	CbGbCtD
Sorafenib—ABCC2—Dexamethasone—ulcerative colitis	0.00708	0.025	CbGbCtD
Sorafenib—CYP1A2—Nicotine—ulcerative colitis	0.0068	0.024	CbGbCtD
Sorafenib—CYP2C19—Cholecalciferol—ulcerative colitis	0.00661	0.0233	CbGbCtD
Sorafenib—ABCG2—Dexamethasone—ulcerative colitis	0.0064	0.0226	CbGbCtD
Sorafenib—CYP2C9—Nicotine—ulcerative colitis	0.00613	0.0216	CbGbCtD
Sorafenib—ABCB1—Methylprednisolone—ulcerative colitis	0.0061	0.0215	CbGbCtD
Sorafenib—CYP3A5—Hydrocortisone—ulcerative colitis	0.0057	0.0201	CbGbCtD
Sorafenib—CYP2D6—Nicotine—ulcerative colitis	0.0056	0.0197	CbGbCtD
Sorafenib—CYP2C9—Cholecalciferol—ulcerative colitis	0.0055	0.0194	CbGbCtD
Sorafenib—CYP2C8—Hydrocortisone—ulcerative colitis	0.00548	0.0193	CbGbCtD
Sorafenib—CYP2D6—Cholecalciferol—ulcerative colitis	0.00503	0.0177	CbGbCtD
Sorafenib—CYP3A7—Dexamethasone—ulcerative colitis	0.00473	0.0167	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Dexamethasone—ulcerative colitis	0.00473	0.0167	CbGbCtD
Sorafenib—CYP2C19—Prednisone—ulcerative colitis	0.00458	0.0161	CbGbCtD
Sorafenib—CYP2B6—Dexamethasone—ulcerative colitis	0.0045	0.0159	CbGbCtD
Sorafenib—KIT—myenteric nerve plexus—ulcerative colitis	0.00403	0.0728	CbGeAlD
Sorafenib—ABCB1—Betamethasone—ulcerative colitis	0.00397	0.014	CbGbCtD
Sorafenib—ABCB1—Prednisolone—ulcerative colitis	0.00392	0.0138	CbGbCtD
Sorafenib—ABCB1—Hydrocortisone—ulcerative colitis	0.00371	0.0131	CbGbCtD
Sorafenib—ABCB1—Prednisone—ulcerative colitis	0.0037	0.013	CbGbCtD
Sorafenib—CYP3A4—Methylprednisolone—ulcerative colitis	0.00366	0.0129	CbGbCtD
Sorafenib—CYP3A4—Nicotine—ulcerative colitis	0.00356	0.0126	CbGbCtD
Sorafenib—CYP3A5—Dexamethasone—ulcerative colitis	0.00355	0.0125	CbGbCtD
Sorafenib—CYP2C8—Dexamethasone—ulcerative colitis	0.00341	0.012	CbGbCtD
Sorafenib—CYP3A4—Cholecalciferol—ulcerative colitis	0.0032	0.0113	CbGbCtD
Sorafenib—CYP2C19—Dexamethasone—ulcerative colitis	0.00286	0.0101	CbGbCtD
Sorafenib—CYP3A4—Triamcinolone—ulcerative colitis	0.00277	0.00976	CbGbCtD
Sorafenib—ABCC2—bile duct—ulcerative colitis	0.00273	0.0494	CbGeAlD
Sorafenib—CYP2C9—Dexamethasone—ulcerative colitis	0.00238	0.00838	CbGbCtD
Sorafenib—CYP3A4—Betamethasone—ulcerative colitis	0.00238	0.00838	CbGbCtD
Sorafenib—CYP3A4—Prednisolone—ulcerative colitis	0.00235	0.00827	CbGbCtD
Sorafenib—ABCB1—Dexamethasone—ulcerative colitis	0.00231	0.00813	CbGbCtD
Sorafenib—CYP3A4—Hydrocortisone—ulcerative colitis	0.00222	0.00784	CbGbCtD
Sorafenib—CYP3A4—Prednisone—ulcerative colitis	0.00222	0.00781	CbGbCtD
Sorafenib—CYP2D6—Dexamethasone—ulcerative colitis	0.00218	0.00766	CbGbCtD
Sorafenib—ABCC2—bile—ulcerative colitis	0.0021	0.038	CbGeAlD
Sorafenib—CYP3A4—Dexamethasone—ulcerative colitis	0.00138	0.00487	CbGbCtD
Sorafenib—TIE1—epithelium—ulcerative colitis	0.000833	0.0151	CbGeAlD
Sorafenib—CDK7—lymphoid tissue—ulcerative colitis	0.000811	0.0147	CbGeAlD
Sorafenib—TIE1—smooth muscle tissue—ulcerative colitis	0.000803	0.0145	CbGeAlD
Sorafenib—ZAK—lymphoid tissue—ulcerative colitis	0.000701	0.0127	CbGeAlD
Sorafenib—ZAK—digestive system—ulcerative colitis	0.000693	0.0125	CbGeAlD
Sorafenib—FLT4—epithelium—ulcerative colitis	0.000688	0.0124	CbGeAlD
Sorafenib—HIPK3—digestive system—ulcerative colitis	0.000678	0.0123	CbGeAlD
Sorafenib—MKNK2—epithelium—ulcerative colitis	0.000623	0.0113	CbGeAlD
Sorafenib—MAP3K7—smooth muscle tissue—ulcerative colitis	0.000619	0.0112	CbGeAlD
Sorafenib—RET—epithelium—ulcerative colitis	0.000608	0.011	CbGeAlD
Sorafenib—MKNK2—smooth muscle tissue—ulcerative colitis	0.0006	0.0108	CbGeAlD
Sorafenib—CDK7—liver—ulcerative colitis	0.000597	0.0108	CbGeAlD
Sorafenib—TAOK2—liver—ulcerative colitis	0.000592	0.0107	CbGeAlD
Sorafenib—FLT3—lymphoid tissue—ulcerative colitis	0.000584	0.0105	CbGeAlD
Sorafenib—RALBP1—smooth muscle tissue—ulcerative colitis	0.000542	0.0098	CbGeAlD
Sorafenib—FLT1—epithelium—ulcerative colitis	0.000535	0.00967	CbGeAlD
Sorafenib—RAF1—epithelium—ulcerative colitis	0.000532	0.00961	CbGeAlD
Sorafenib—UGT1A9—digestive system—ulcerative colitis	0.000531	0.0096	CbGeAlD
Sorafenib—FLT4—lymphoid tissue—ulcerative colitis	0.00053	0.00958	CbGeAlD
Sorafenib—ZAK—liver—ulcerative colitis	0.000516	0.00933	CbGeAlD
Sorafenib—FLT1—smooth muscle tissue—ulcerative colitis	0.000516	0.00932	CbGeAlD
Sorafenib—RAF1—smooth muscle tissue—ulcerative colitis	0.000513	0.00926	CbGeAlD
Sorafenib—Regorafenib—ABCB1—ulcerative colitis	0.000506	0.381	CrCbGaD
Sorafenib—HIPK3—liver—ulcerative colitis	0.000505	0.00913	CbGeAlD
Sorafenib—PDGFRA—smooth muscle tissue—ulcerative colitis	0.000483	0.00873	CbGeAlD
Sorafenib—MKNK2—lymphoid tissue—ulcerative colitis	0.00048	0.00867	CbGeAlD
Sorafenib—MKNK2—digestive system—ulcerative colitis	0.000474	0.00856	CbGeAlD
Sorafenib—MKNK1—lymphoid tissue—ulcerative colitis	0.000474	0.00856	CbGeAlD
Sorafenib—TIE1—liver—ulcerative colitis	0.000472	0.00853	CbGeAlD
Sorafenib—MKNK1—digestive system—ulcerative colitis	0.000468	0.00846	CbGeAlD
Sorafenib—RET—lymphoid tissue—ulcerative colitis	0.000468	0.00846	CbGeAlD
Sorafenib—RET—digestive system—ulcerative colitis	0.000462	0.00835	CbGeAlD
Sorafenib—BRAF—liver—ulcerative colitis	0.000453	0.00818	CbGeAlD
Sorafenib—KDR—epithelium—ulcerative colitis	0.000452	0.00817	CbGeAlD
Sorafenib—KDR—smooth muscle tissue—ulcerative colitis	0.000436	0.00788	CbGeAlD
Sorafenib—EPHX2—liver—ulcerative colitis	0.000433	0.00782	CbGeAlD
Sorafenib—FLT3—liver—ulcerative colitis	0.000429	0.00776	CbGeAlD
Sorafenib—RALBP1—digestive system—ulcerative colitis	0.000428	0.00773	CbGeAlD
Sorafenib—CSF1R—smooth muscle tissue—ulcerative colitis	0.000425	0.00769	CbGeAlD
Sorafenib—Vismodegib—ALB—ulcerative colitis	0.00042	0.317	CrCbGaD
Sorafenib—FLT1—lymphoid tissue—ulcerative colitis	0.000412	0.00745	CbGeAlD
Sorafenib—RAF1—lymphoid tissue—ulcerative colitis	0.00041	0.0074	CbGeAlD
Sorafenib—FLT1—digestive system—ulcerative colitis	0.000407	0.00736	CbGeAlD
Sorafenib—RAF1—digestive system—ulcerative colitis	0.000405	0.00731	CbGeAlD
Sorafenib—Vismodegib—ABCB1—ulcerative colitis	0.000401	0.302	CrCbGaD
Sorafenib—KIT—epithelium—ulcerative colitis	0.000401	0.00724	CbGeAlD
Sorafenib—UGT1A9—liver—ulcerative colitis	0.000396	0.00715	CbGeAlD
Sorafenib—PDGFRB—epithelium—ulcerative colitis	0.000392	0.00707	CbGeAlD
Sorafenib—STK10—lymphoid tissue—ulcerative colitis	0.00039	0.00705	CbGeAlD
Sorafenib—FLT4—liver—ulcerative colitis	0.00039	0.00705	CbGeAlD
Sorafenib—KIT—smooth muscle tissue—ulcerative colitis	0.000386	0.00698	CbGeAlD
Sorafenib—PDGFRA—lymphoid tissue—ulcerative colitis	0.000386	0.00698	CbGeAlD
Sorafenib—STK10—digestive system—ulcerative colitis	0.000385	0.00696	CbGeAlD
Sorafenib—FGFR1—liver—ulcerative colitis	0.000385	0.00695	CbGeAlD
Sorafenib—PDGFRA—digestive system—ulcerative colitis	0.000381	0.00689	CbGeAlD
Sorafenib—PDGFRB—smooth muscle tissue—ulcerative colitis	0.000377	0.00682	CbGeAlD
Sorafenib—MAP3K7—liver—ulcerative colitis	0.000364	0.00658	CbGeAlD
Sorafenib—UGT1A1—digestive system—ulcerative colitis	0.000364	0.00658	CbGeAlD
Sorafenib—MKNK2—liver—ulcerative colitis	0.000353	0.00638	CbGeAlD
Sorafenib—MKNK1—liver—ulcerative colitis	0.000349	0.0063	CbGeAlD
Sorafenib—KDR—lymphoid tissue—ulcerative colitis	0.000348	0.0063	CbGeAlD
Sorafenib—KDR—digestive system—ulcerative colitis	0.000344	0.00622	CbGeAlD
Sorafenib—CSF1R—lymphoid tissue—ulcerative colitis	0.00034	0.00614	CbGeAlD
Sorafenib—CSF1R—digestive system—ulcerative colitis	0.000336	0.00607	CbGeAlD
Sorafenib—CYP3A7—liver—ulcerative colitis	0.000329	0.00594	CbGeAlD
Sorafenib—RALBP1—liver—ulcerative colitis	0.000319	0.00576	CbGeAlD
Sorafenib—KIT—lymphoid tissue—ulcerative colitis	0.000309	0.00558	CbGeAlD
Sorafenib—KIT—digestive system—ulcerative colitis	0.000305	0.00551	CbGeAlD
Sorafenib—FLT1—liver—ulcerative colitis	0.000303	0.00548	CbGeAlD
Sorafenib—PDGFRB—lymphoid tissue—ulcerative colitis	0.000302	0.00545	CbGeAlD
Sorafenib—RAF1—liver—ulcerative colitis	0.000302	0.00545	CbGeAlD
Sorafenib—HTR2B—smooth muscle tissue—ulcerative colitis	0.000299	0.0054	CbGeAlD
Sorafenib—PDGFRB—digestive system—ulcerative colitis	0.000298	0.00538	CbGeAlD
Sorafenib—STK10—liver—ulcerative colitis	0.000287	0.00519	CbGeAlD
Sorafenib—PDGFRA—liver—ulcerative colitis	0.000284	0.00514	CbGeAlD
Sorafenib—CYP3A7-CYP3A51P—liver—ulcerative colitis	0.00028	0.00505	CbGeAlD
Sorafenib—UGT1A1—liver—ulcerative colitis	0.000271	0.0049	CbGeAlD
Sorafenib—KDR—liver—ulcerative colitis	0.000256	0.00463	CbGeAlD
Sorafenib—MAP2K5—liver—ulcerative colitis	0.000256	0.00463	CbGeAlD
Sorafenib—CSF1R—liver—ulcerative colitis	0.00025	0.00452	CbGeAlD
Sorafenib—ABCC4—digestive system—ulcerative colitis	0.000237	0.00429	CbGeAlD
Sorafenib—HTR2B—digestive system—ulcerative colitis	0.000236	0.00426	CbGeAlD
Sorafenib—ABCC2—digestive system—ulcerative colitis	0.00023	0.00415	CbGeAlD
Sorafenib—KIT—liver—ulcerative colitis	0.000227	0.00411	CbGeAlD
Sorafenib—PDGFRB—liver—ulcerative colitis	0.000222	0.00401	CbGeAlD
Sorafenib—CYP2C19—digestive system—ulcerative colitis	0.000197	0.00356	CbGeAlD
Sorafenib—ABCC4—liver—ulcerative colitis	0.000177	0.00319	CbGeAlD
Sorafenib—ABCC2—liver—ulcerative colitis	0.000171	0.00309	CbGeAlD
Sorafenib—CYP1A2—digestive system—ulcerative colitis	0.000161	0.00291	CbGeAlD
Sorafenib—CYP2B6—lymphoid tissue—ulcerative colitis	0.000156	0.00283	CbGeAlD
Sorafenib—CYP3A5—digestive system—ulcerative colitis	0.000155	0.00281	CbGeAlD
Sorafenib—CYP2B6—digestive system—ulcerative colitis	0.000154	0.00279	CbGeAlD
Sorafenib—CYP2C9—digestive system—ulcerative colitis	0.000153	0.00276	CbGeAlD
Sorafenib—CYP2C19—liver—ulcerative colitis	0.000147	0.00266	CbGeAlD
Sorafenib—CYP2C8—liver—ulcerative colitis	0.000128	0.00232	CbGeAlD
Sorafenib—ABCG2—liver—ulcerative colitis	0.000125	0.00225	CbGeAlD
Sorafenib—CYP1A2—liver—ulcerative colitis	0.00012	0.00217	CbGeAlD
Sorafenib—CYP3A4—digestive system—ulcerative colitis	0.000117	0.00211	CbGeAlD
Sorafenib—CYP3A5—liver—ulcerative colitis	0.000116	0.00209	CbGeAlD
Sorafenib—CYP2B6—liver—ulcerative colitis	0.000115	0.00208	CbGeAlD
Sorafenib—CYP2D6—digestive system—ulcerative colitis	0.000115	0.00207	CbGeAlD
Sorafenib—CYP2C9—liver—ulcerative colitis	0.000114	0.00206	CbGeAlD
Sorafenib—ABCB1—epithelium—ulcerative colitis	0.000109	0.00196	CbGeAlD
Sorafenib—CYP3A4—liver—ulcerative colitis	8.69e-05	0.00157	CbGeAlD
Sorafenib—CYP2D6—liver—ulcerative colitis	8.55e-05	0.00155	CbGeAlD
Sorafenib—ABCB1—lymphoid tissue—ulcerative colitis	8.36e-05	0.00151	CbGeAlD
Sorafenib—ABCB1—digestive system—ulcerative colitis	8.26e-05	0.00149	CbGeAlD
Sorafenib—Diarrhoea—Budesonide—ulcerative colitis	7.58e-05	0.000846	CcSEcCtD
Sorafenib—Arrhythmia—Methylprednisolone—ulcerative colitis	7.57e-05	0.000845	CcSEcCtD
Sorafenib—Mental disorder—Methylprednisolone—ulcerative colitis	7.43e-05	0.000829	CcSEcCtD
Sorafenib—Erythema—Triamcinolone—ulcerative colitis	7.39e-05	0.000825	CcSEcCtD
Sorafenib—Malnutrition—Methylprednisolone—ulcerative colitis	7.38e-05	0.000824	CcSEcCtD
Sorafenib—Erythema—Methylprednisolone—ulcerative colitis	7.38e-05	0.000824	CcSEcCtD
Sorafenib—Acute coronary syndrome—Prednisone—ulcerative colitis	7.37e-05	0.000823	CcSEcCtD
Sorafenib—Gastrointestinal pain—Mesalazine—ulcerative colitis	7.37e-05	0.000823	CcSEcCtD
Sorafenib—Angioedema—Prednisolone—ulcerative colitis	7.35e-05	0.00082	CcSEcCtD
Sorafenib—Myocardial infarction—Prednisone—ulcerative colitis	7.33e-05	0.000818	CcSEcCtD
Sorafenib—Neuropathy peripheral—Prednisone—ulcerative colitis	7.33e-05	0.000818	CcSEcCtD
Sorafenib—Dizziness—Budesonide—ulcerative colitis	7.33e-05	0.000818	CcSEcCtD
Sorafenib—Hypersensitivity—Azathioprine—ulcerative colitis	7.29e-05	0.000814	CcSEcCtD
Sorafenib—Dysgeusia—Triamcinolone—ulcerative colitis	7.24e-05	0.000808	CcSEcCtD
Sorafenib—Syncope—Prednisolone—ulcerative colitis	7.21e-05	0.000805	CcSEcCtD
Sorafenib—Angioedema—Hydrocortisone—ulcerative colitis	7.18e-05	0.000801	CcSEcCtD
Sorafenib—Urticaria—Mesalazine—ulcerative colitis	7.16e-05	0.000799	CcSEcCtD
Sorafenib—Abdominal pain—Mesalazine—ulcerative colitis	7.13e-05	0.000795	CcSEcCtD
Sorafenib—Body temperature increased—Mesalazine—ulcerative colitis	7.13e-05	0.000795	CcSEcCtD
Sorafenib—Loss of consciousness—Prednisolone—ulcerative colitis	7.07e-05	0.000789	CcSEcCtD
Sorafenib—Vomiting—Budesonide—ulcerative colitis	7.05e-05	0.000787	CcSEcCtD
Sorafenib—Syncope—Hydrocortisone—ulcerative colitis	7.04e-05	0.000786	CcSEcCtD
Sorafenib—Angiopathy—Dexamethasone—ulcerative colitis	6.99e-05	0.000781	CcSEcCtD
Sorafenib—Angiopathy—Betamethasone—ulcerative colitis	6.99e-05	0.000781	CcSEcCtD
Sorafenib—Rash—Budesonide—ulcerative colitis	6.99e-05	0.00078	CcSEcCtD
Sorafenib—Dermatitis—Budesonide—ulcerative colitis	6.98e-05	0.000779	CcSEcCtD
Sorafenib—Headache—Budesonide—ulcerative colitis	6.94e-05	0.000775	CcSEcCtD
Sorafenib—Hypertension—Prednisolone—ulcerative colitis	6.94e-05	0.000775	CcSEcCtD
Sorafenib—Loss of consciousness—Hydrocortisone—ulcerative colitis	6.9e-05	0.00077	CcSEcCtD
Sorafenib—Arrhythmia—Betamethasone—ulcerative colitis	6.89e-05	0.000769	CcSEcCtD
Sorafenib—Arrhythmia—Dexamethasone—ulcerative colitis	6.89e-05	0.000769	CcSEcCtD
Sorafenib—Alopecia—Betamethasone—ulcerative colitis	6.81e-05	0.00076	CcSEcCtD
Sorafenib—Alopecia—Dexamethasone—ulcerative colitis	6.81e-05	0.00076	CcSEcCtD
Sorafenib—Hypertension—Hydrocortisone—ulcerative colitis	6.78e-05	0.000757	CcSEcCtD
Sorafenib—Diarrhoea—Azathioprine—ulcerative colitis	6.77e-05	0.000756	CcSEcCtD
Sorafenib—Angioedema—Triamcinolone—ulcerative colitis	6.76e-05	0.000754	CcSEcCtD
Sorafenib—Haemoglobin—Prednisone—ulcerative colitis	6.75e-05	0.000753	CcSEcCtD
Sorafenib—Angioedema—Methylprednisolone—ulcerative colitis	6.74e-05	0.000753	CcSEcCtD
Sorafenib—Haemorrhage—Prednisone—ulcerative colitis	6.71e-05	0.000749	CcSEcCtD
Sorafenib—Erythema—Betamethasone—ulcerative colitis	6.71e-05	0.000749	CcSEcCtD
Sorafenib—Erythema—Dexamethasone—ulcerative colitis	6.71e-05	0.000749	CcSEcCtD
Sorafenib—Myalgia—Hydrocortisone—ulcerative colitis	6.69e-05	0.000746	CcSEcCtD
Sorafenib—Hypersensitivity—Mesalazine—ulcerative colitis	6.64e-05	0.000741	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—ulcerative colitis	6.64e-05	0.000741	CcSEcCtD
Sorafenib—Syncope—Triamcinolone—ulcerative colitis	6.63e-05	0.00074	CcSEcCtD
Sorafenib—Syncope—Methylprednisolone—ulcerative colitis	6.62e-05	0.000739	CcSEcCtD
Sorafenib—Connective tissue disorder—Prednisone—ulcerative colitis	6.6e-05	0.000736	CcSEcCtD
Sorafenib—Nausea—Budesonide—ulcerative colitis	6.58e-05	0.000735	CcSEcCtD
Sorafenib—Anaphylactic shock—Prednisolone—ulcerative colitis	6.56e-05	0.000733	CcSEcCtD
Sorafenib—Dizziness—Azathioprine—ulcerative colitis	6.54e-05	0.00073	CcSEcCtD
Sorafenib—Loss of consciousness—Triamcinolone—ulcerative colitis	6.5e-05	0.000725	CcSEcCtD
Sorafenib—Loss of consciousness—Methylprednisolone—ulcerative colitis	6.48e-05	0.000724	CcSEcCtD
Sorafenib—Asthenia—Mesalazine—ulcerative colitis	6.47e-05	0.000722	CcSEcCtD
Sorafenib—Shock—Prednisolone—ulcerative colitis	6.46e-05	0.000721	CcSEcCtD
Sorafenib—Cough—Triamcinolone—ulcerative colitis	6.45e-05	0.00072	CcSEcCtD
Sorafenib—Anaphylactic shock—Hydrocortisone—ulcerative colitis	6.41e-05	0.000715	CcSEcCtD
Sorafenib—Hypertension—Triamcinolone—ulcerative colitis	6.38e-05	0.000713	CcSEcCtD
Sorafenib—Pruritus—Mesalazine—ulcerative colitis	6.38e-05	0.000712	CcSEcCtD
Sorafenib—Hypertension—Methylprednisolone—ulcerative colitis	6.37e-05	0.000711	CcSEcCtD
Sorafenib—Infection—Hydrocortisone—ulcerative colitis	6.37e-05	0.000711	CcSEcCtD
Sorafenib—Shock—Hydrocortisone—ulcerative colitis	6.31e-05	0.000704	CcSEcCtD
Sorafenib—Myalgia—Triamcinolone—ulcerative colitis	6.3e-05	0.000703	CcSEcCtD
Sorafenib—Vomiting—Azathioprine—ulcerative colitis	6.29e-05	0.000702	CcSEcCtD
Sorafenib—Nervous system disorder—Hydrocortisone—ulcerative colitis	6.29e-05	0.000702	CcSEcCtD
Sorafenib—Arthralgia—Methylprednisolone—ulcerative colitis	6.28e-05	0.000701	CcSEcCtD
Sorafenib—Myalgia—Methylprednisolone—ulcerative colitis	6.28e-05	0.000701	CcSEcCtD
Sorafenib—Rash—Azathioprine—ulcerative colitis	6.24e-05	0.000696	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ulcerative colitis	6.24e-05	0.000696	CcSEcCtD
Sorafenib—Dermatitis—Azathioprine—ulcerative colitis	6.23e-05	0.000696	CcSEcCtD
Sorafenib—Flushing—Prednisone—ulcerative colitis	6.23e-05	0.000695	CcSEcCtD
Sorafenib—Skin disorder—Hydrocortisone—ulcerative colitis	6.23e-05	0.000695	CcSEcCtD
Sorafenib—Headache—Azathioprine—ulcerative colitis	6.2e-05	0.000692	CcSEcCtD
Sorafenib—Diarrhoea—Mesalazine—ulcerative colitis	6.17e-05	0.000688	CcSEcCtD
Sorafenib—Dry mouth—Triamcinolone—ulcerative colitis	6.16e-05	0.000687	CcSEcCtD
Sorafenib—ABCB1—liver—ulcerative colitis	6.15e-05	0.00111	CbGeAlD
Sorafenib—Angioedema—Betamethasone—ulcerative colitis	6.13e-05	0.000684	CcSEcCtD
Sorafenib—Angioedema—Dexamethasone—ulcerative colitis	6.13e-05	0.000684	CcSEcCtD
Sorafenib—Anorexia—Hydrocortisone—ulcerative colitis	6.11e-05	0.000682	CcSEcCtD
Sorafenib—Angiopathy—Prednisone—ulcerative colitis	6.09e-05	0.00068	CcSEcCtD
Sorafenib—Immune system disorder—Prednisone—ulcerative colitis	6.06e-05	0.000677	CcSEcCtD
Sorafenib—Anaphylactic shock—Triamcinolone—ulcerative colitis	6.04e-05	0.000674	CcSEcCtD
Sorafenib—Anaphylactic shock—Methylprednisolone—ulcerative colitis	6.02e-05	0.000672	CcSEcCtD
Sorafenib—Syncope—Betamethasone—ulcerative colitis	6.02e-05	0.000672	CcSEcCtD
Sorafenib—Syncope—Dexamethasone—ulcerative colitis	6.02e-05	0.000672	CcSEcCtD
Sorafenib—Arrhythmia—Prednisone—ulcerative colitis	6e-05	0.000669	CcSEcCtD
Sorafenib—Infection—Triamcinolone—ulcerative colitis	6e-05	0.000669	CcSEcCtD
Sorafenib—Infection—Methylprednisolone—ulcerative colitis	5.98e-05	0.000668	CcSEcCtD
Sorafenib—Dizziness—Mesalazine—ulcerative colitis	5.96e-05	0.000665	CcSEcCtD
Sorafenib—Shock—Triamcinolone—ulcerative colitis	5.94e-05	0.000663	CcSEcCtD
Sorafenib—Alopecia—Prednisone—ulcerative colitis	5.93e-05	0.000662	CcSEcCtD
Sorafenib—Shock—Methylprednisolone—ulcerative colitis	5.92e-05	0.000661	CcSEcCtD
Sorafenib—Nervous system disorder—Methylprednisolone—ulcerative colitis	5.91e-05	0.000659	CcSEcCtD
Sorafenib—Loss of consciousness—Betamethasone—ulcerative colitis	5.9e-05	0.000658	CcSEcCtD
Sorafenib—Loss of consciousness—Dexamethasone—ulcerative colitis	5.9e-05	0.000658	CcSEcCtD
Sorafenib—Mental disorder—Prednisone—ulcerative colitis	5.88e-05	0.000656	CcSEcCtD
Sorafenib—Nausea—Azathioprine—ulcerative colitis	5.88e-05	0.000656	CcSEcCtD
Sorafenib—Skin disorder—Methylprednisolone—ulcerative colitis	5.85e-05	0.000653	CcSEcCtD
Sorafenib—Erythema—Prednisone—ulcerative colitis	5.84e-05	0.000652	CcSEcCtD
Sorafenib—Malnutrition—Prednisone—ulcerative colitis	5.84e-05	0.000652	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Hydrocortisone—ulcerative colitis	5.84e-05	0.000652	CcSEcCtD
Sorafenib—Hypertension—Dexamethasone—ulcerative colitis	5.79e-05	0.000647	CcSEcCtD
Sorafenib—Hypertension—Betamethasone—ulcerative colitis	5.79e-05	0.000647	CcSEcCtD
Sorafenib—Vomiting—Mesalazine—ulcerative colitis	5.73e-05	0.00064	CcSEcCtD
Sorafenib—Myalgia—Dexamethasone—ulcerative colitis	5.71e-05	0.000638	CcSEcCtD
Sorafenib—Myalgia—Betamethasone—ulcerative colitis	5.71e-05	0.000638	CcSEcCtD
Sorafenib—Rash—Mesalazine—ulcerative colitis	5.68e-05	0.000634	CcSEcCtD
Sorafenib—Dermatitis—Mesalazine—ulcerative colitis	5.68e-05	0.000634	CcSEcCtD
Sorafenib—Headache—Mesalazine—ulcerative colitis	5.65e-05	0.00063	CcSEcCtD
Sorafenib—Dyspepsia—Hydrocortisone—ulcerative colitis	5.64e-05	0.00063	CcSEcCtD
Sorafenib—Pain—Prednisolone—ulcerative colitis	5.61e-05	0.000626	CcSEcCtD
Sorafenib—Decreased appetite—Hydrocortisone—ulcerative colitis	5.57e-05	0.000622	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Hydrocortisone—ulcerative colitis	5.53e-05	0.000618	CcSEcCtD
Sorafenib—Fatigue—Hydrocortisone—ulcerative colitis	5.53e-05	0.000617	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Triamcinolone—ulcerative colitis	5.5e-05	0.000614	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Methylprednisolone—ulcerative colitis	5.49e-05	0.000612	CcSEcCtD
Sorafenib—Pain—Hydrocortisone—ulcerative colitis	5.48e-05	0.000612	CcSEcCtD
Sorafenib—Anaphylactic shock—Dexamethasone—ulcerative colitis	5.48e-05	0.000611	CcSEcCtD
Sorafenib—Anaphylactic shock—Betamethasone—ulcerative colitis	5.48e-05	0.000611	CcSEcCtD
Sorafenib—Infection—Betamethasone—ulcerative colitis	5.44e-05	0.000607	CcSEcCtD
Sorafenib—Infection—Dexamethasone—ulcerative colitis	5.44e-05	0.000607	CcSEcCtD
Sorafenib—Anaemia—Prednisone—ulcerative colitis	5.4e-05	0.000603	CcSEcCtD
Sorafenib—Shock—Dexamethasone—ulcerative colitis	5.39e-05	0.000601	CcSEcCtD
Sorafenib—Shock—Betamethasone—ulcerative colitis	5.39e-05	0.000601	CcSEcCtD
Sorafenib—Dyspnoea—Triamcinolone—ulcerative colitis	5.38e-05	0.000601	CcSEcCtD
Sorafenib—Nervous system disorder—Dexamethasone—ulcerative colitis	5.37e-05	0.000599	CcSEcCtD
Sorafenib—Nervous system disorder—Betamethasone—ulcerative colitis	5.37e-05	0.000599	CcSEcCtD
Sorafenib—Thrombocytopenia—Betamethasone—ulcerative colitis	5.36e-05	0.000598	CcSEcCtD
Sorafenib—Thrombocytopenia—Dexamethasone—ulcerative colitis	5.36e-05	0.000598	CcSEcCtD
Sorafenib—Nausea—Mesalazine—ulcerative colitis	5.35e-05	0.000598	CcSEcCtD
Sorafenib—Angioedema—Prednisone—ulcerative colitis	5.34e-05	0.000596	CcSEcCtD
Sorafenib—Dyspepsia—Triamcinolone—ulcerative colitis	5.31e-05	0.000593	CcSEcCtD
Sorafenib—Dyspepsia—Methylprednisolone—ulcerative colitis	5.3e-05	0.000592	CcSEcCtD
Sorafenib—Gastrointestinal pain—Hydrocortisone—ulcerative colitis	5.24e-05	0.000585	CcSEcCtD
Sorafenib—Syncope—Prednisone—ulcerative colitis	5.24e-05	0.000585	CcSEcCtD
Sorafenib—Anorexia—Dexamethasone—ulcerative colitis	5.22e-05	0.000583	CcSEcCtD
Sorafenib—Anorexia—Betamethasone—ulcerative colitis	5.22e-05	0.000583	CcSEcCtD
Sorafenib—Urticaria—Prednisolone—ulcerative colitis	5.21e-05	0.000582	CcSEcCtD
Sorafenib—Fatigue—Triamcinolone—ulcerative colitis	5.2e-05	0.000581	CcSEcCtD
Sorafenib—Fatigue—Methylprednisolone—ulcerative colitis	5.19e-05	0.000579	CcSEcCtD
Sorafenib—Pain—Triamcinolone—ulcerative colitis	5.16e-05	0.000576	CcSEcCtD
Sorafenib—Loss of consciousness—Prednisone—ulcerative colitis	5.14e-05	0.000573	CcSEcCtD
Sorafenib—Urticaria—Hydrocortisone—ulcerative colitis	5.09e-05	0.000568	CcSEcCtD
Sorafenib—Body temperature increased—Hydrocortisone—ulcerative colitis	5.07e-05	0.000566	CcSEcCtD
Sorafenib—Abdominal pain—Hydrocortisone—ulcerative colitis	5.07e-05	0.000566	CcSEcCtD
Sorafenib—Hypertension—Prednisone—ulcerative colitis	5.04e-05	0.000563	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Betamethasone—ulcerative colitis	4.99e-05	0.000557	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Dexamethasone—ulcerative colitis	4.99e-05	0.000557	CcSEcCtD
Sorafenib—Arthralgia—Prednisone—ulcerative colitis	4.97e-05	0.000555	CcSEcCtD
Sorafenib—Myalgia—Prednisone—ulcerative colitis	4.97e-05	0.000555	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ulcerative colitis	4.94e-05	0.000551	CcSEcCtD
Sorafenib—Gastrointestinal pain—Methylprednisolone—ulcerative colitis	4.92e-05	0.00055	CcSEcCtD
Sorafenib—Hypersensitivity—Prednisolone—ulcerative colitis	4.84e-05	0.00054	CcSEcCtD
Sorafenib—Dyspepsia—Dexamethasone—ulcerative colitis	4.82e-05	0.000538	CcSEcCtD
Sorafenib—Dyspepsia—Betamethasone—ulcerative colitis	4.82e-05	0.000538	CcSEcCtD
Sorafenib—Urticaria—Triamcinolone—ulcerative colitis	4.79e-05	0.000535	CcSEcCtD
Sorafenib—Urticaria—Methylprednisolone—ulcerative colitis	4.78e-05	0.000534	CcSEcCtD
Sorafenib—Body temperature increased—Triamcinolone—ulcerative colitis	4.77e-05	0.000533	CcSEcCtD
Sorafenib—Anaphylactic shock—Prednisone—ulcerative colitis	4.77e-05	0.000532	CcSEcCtD
Sorafenib—Abdominal pain—Methylprednisolone—ulcerative colitis	4.76e-05	0.000531	CcSEcCtD
Sorafenib—Decreased appetite—Betamethasone—ulcerative colitis	4.76e-05	0.000531	CcSEcCtD
Sorafenib—Decreased appetite—Dexamethasone—ulcerative colitis	4.76e-05	0.000531	CcSEcCtD
Sorafenib—Infection—Prednisone—ulcerative colitis	4.74e-05	0.000529	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Dexamethasone—ulcerative colitis	4.73e-05	0.000528	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Betamethasone—ulcerative colitis	4.73e-05	0.000528	CcSEcCtD
Sorafenib—Hypersensitivity—Hydrocortisone—ulcerative colitis	4.72e-05	0.000527	CcSEcCtD
Sorafenib—Fatigue—Betamethasone—ulcerative colitis	4.72e-05	0.000527	CcSEcCtD
Sorafenib—Fatigue—Dexamethasone—ulcerative colitis	4.72e-05	0.000527	CcSEcCtD
Sorafenib—Shock—Prednisone—ulcerative colitis	4.69e-05	0.000524	CcSEcCtD
Sorafenib—Pain—Dexamethasone—ulcerative colitis	4.68e-05	0.000523	CcSEcCtD
Sorafenib—Pain—Betamethasone—ulcerative colitis	4.68e-05	0.000523	CcSEcCtD
Sorafenib—Nervous system disorder—Prednisone—ulcerative colitis	4.68e-05	0.000522	CcSEcCtD
Sorafenib—Skin disorder—Prednisone—ulcerative colitis	4.63e-05	0.000517	CcSEcCtD
Sorafenib—Asthenia—Hydrocortisone—ulcerative colitis	4.6e-05	0.000513	CcSEcCtD
Sorafenib—Anorexia—Prednisone—ulcerative colitis	4.55e-05	0.000507	CcSEcCtD
Sorafenib—Pruritus—Hydrocortisone—ulcerative colitis	4.53e-05	0.000506	CcSEcCtD
Sorafenib—Gastrointestinal pain—Betamethasone—ulcerative colitis	4.48e-05	0.0005	CcSEcCtD
Sorafenib—Gastrointestinal pain—Dexamethasone—ulcerative colitis	4.48e-05	0.0005	CcSEcCtD
Sorafenib—Hypersensitivity—Triamcinolone—ulcerative colitis	4.45e-05	0.000496	CcSEcCtD
Sorafenib—Hypersensitivity—Methylprednisolone—ulcerative colitis	4.44e-05	0.000495	CcSEcCtD
Sorafenib—Diarrhoea—Hydrocortisone—ulcerative colitis	4.39e-05	0.000489	CcSEcCtD
Sorafenib—Urticaria—Dexamethasone—ulcerative colitis	4.35e-05	0.000486	CcSEcCtD
Sorafenib—Urticaria—Betamethasone—ulcerative colitis	4.35e-05	0.000486	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Prednisone—ulcerative colitis	4.34e-05	0.000485	CcSEcCtD
Sorafenib—Dizziness—Prednisolone—ulcerative colitis	4.34e-05	0.000484	CcSEcCtD
Sorafenib—Asthenia—Triamcinolone—ulcerative colitis	4.33e-05	0.000483	CcSEcCtD
Sorafenib—Body temperature increased—Dexamethasone—ulcerative colitis	4.33e-05	0.000483	CcSEcCtD
Sorafenib—Abdominal pain—Dexamethasone—ulcerative colitis	4.33e-05	0.000483	CcSEcCtD
Sorafenib—Body temperature increased—Betamethasone—ulcerative colitis	4.33e-05	0.000483	CcSEcCtD
Sorafenib—Abdominal pain—Betamethasone—ulcerative colitis	4.33e-05	0.000483	CcSEcCtD
Sorafenib—Asthenia—Methylprednisolone—ulcerative colitis	4.32e-05	0.000482	CcSEcCtD
Sorafenib—Pruritus—Triamcinolone—ulcerative colitis	4.27e-05	0.000477	CcSEcCtD
Sorafenib—Pruritus—Methylprednisolone—ulcerative colitis	4.26e-05	0.000476	CcSEcCtD
Sorafenib—Dizziness—Hydrocortisone—ulcerative colitis	4.24e-05	0.000473	CcSEcCtD
Sorafenib—Dyspepsia—Prednisone—ulcerative colitis	4.2e-05	0.000469	CcSEcCtD
Sorafenib—Decreased appetite—Prednisone—ulcerative colitis	4.15e-05	0.000463	CcSEcCtD
Sorafenib—Rash—Prednisolone—ulcerative colitis	4.14e-05	0.000462	CcSEcCtD
Sorafenib—Dermatitis—Prednisolone—ulcerative colitis	4.13e-05	0.000461	CcSEcCtD
Sorafenib—Diarrhoea—Methylprednisolone—ulcerative colitis	4.12e-05	0.00046	CcSEcCtD
Sorafenib—Fatigue—Prednisone—ulcerative colitis	4.11e-05	0.000459	CcSEcCtD
Sorafenib—Headache—Prednisolone—ulcerative colitis	4.11e-05	0.000459	CcSEcCtD
Sorafenib—Constipation—Prednisone—ulcerative colitis	4.08e-05	0.000455	CcSEcCtD
Sorafenib—Vomiting—Hydrocortisone—ulcerative colitis	4.08e-05	0.000455	CcSEcCtD
Sorafenib—Rash—Hydrocortisone—ulcerative colitis	4.04e-05	0.000451	CcSEcCtD
Sorafenib—Dermatitis—Hydrocortisone—ulcerative colitis	4.04e-05	0.000451	CcSEcCtD
Sorafenib—Headache—Hydrocortisone—ulcerative colitis	4.02e-05	0.000448	CcSEcCtD
Sorafenib—Dizziness—Triamcinolone—ulcerative colitis	3.99e-05	0.000445	CcSEcCtD
Sorafenib—Dizziness—Methylprednisolone—ulcerative colitis	3.98e-05	0.000444	CcSEcCtD
Sorafenib—Asthenia—Betamethasone—ulcerative colitis	3.93e-05	0.000439	CcSEcCtD
Sorafenib—Asthenia—Dexamethasone—ulcerative colitis	3.93e-05	0.000439	CcSEcCtD
Sorafenib—Gastrointestinal pain—Prednisone—ulcerative colitis	3.9e-05	0.000435	CcSEcCtD
Sorafenib—Nausea—Prednisolone—ulcerative colitis	3.9e-05	0.000435	CcSEcCtD
Sorafenib—Pruritus—Betamethasone—ulcerative colitis	3.87e-05	0.000432	CcSEcCtD
Sorafenib—Pruritus—Dexamethasone—ulcerative colitis	3.87e-05	0.000432	CcSEcCtD
Sorafenib—Vomiting—Triamcinolone—ulcerative colitis	3.84e-05	0.000428	CcSEcCtD
Sorafenib—Vomiting—Methylprednisolone—ulcerative colitis	3.83e-05	0.000427	CcSEcCtD
Sorafenib—Nausea—Hydrocortisone—ulcerative colitis	3.81e-05	0.000425	CcSEcCtD
Sorafenib—Rash—Triamcinolone—ulcerative colitis	3.81e-05	0.000425	CcSEcCtD
Sorafenib—Dermatitis—Triamcinolone—ulcerative colitis	3.8e-05	0.000424	CcSEcCtD
Sorafenib—Rash—Methylprednisolone—ulcerative colitis	3.8e-05	0.000424	CcSEcCtD
Sorafenib—Dermatitis—Methylprednisolone—ulcerative colitis	3.79e-05	0.000423	CcSEcCtD
Sorafenib—Urticaria—Prednisone—ulcerative colitis	3.79e-05	0.000423	CcSEcCtD
Sorafenib—Headache—Triamcinolone—ulcerative colitis	3.78e-05	0.000422	CcSEcCtD
Sorafenib—Headache—Methylprednisolone—ulcerative colitis	3.77e-05	0.000421	CcSEcCtD
Sorafenib—Body temperature increased—Prednisone—ulcerative colitis	3.77e-05	0.000421	CcSEcCtD
Sorafenib—Abdominal pain—Prednisone—ulcerative colitis	3.77e-05	0.000421	CcSEcCtD
Sorafenib—Diarrhoea—Dexamethasone—ulcerative colitis	3.75e-05	0.000418	CcSEcCtD
Sorafenib—Diarrhoea—Betamethasone—ulcerative colitis	3.75e-05	0.000418	CcSEcCtD
Sorafenib—Dizziness—Dexamethasone—ulcerative colitis	3.62e-05	0.000404	CcSEcCtD
Sorafenib—Dizziness—Betamethasone—ulcerative colitis	3.62e-05	0.000404	CcSEcCtD
Sorafenib—Nausea—Triamcinolone—ulcerative colitis	3.58e-05	0.0004	CcSEcCtD
Sorafenib—Nausea—Methylprednisolone—ulcerative colitis	3.58e-05	0.000399	CcSEcCtD
Sorafenib—Hypersensitivity—Prednisone—ulcerative colitis	3.51e-05	0.000392	CcSEcCtD
Sorafenib—Vomiting—Betamethasone—ulcerative colitis	3.48e-05	0.000389	CcSEcCtD
Sorafenib—Vomiting—Dexamethasone—ulcerative colitis	3.48e-05	0.000389	CcSEcCtD
Sorafenib—Rash—Dexamethasone—ulcerative colitis	3.45e-05	0.000385	CcSEcCtD
Sorafenib—Rash—Betamethasone—ulcerative colitis	3.45e-05	0.000385	CcSEcCtD
Sorafenib—Dermatitis—Dexamethasone—ulcerative colitis	3.45e-05	0.000385	CcSEcCtD
Sorafenib—Dermatitis—Betamethasone—ulcerative colitis	3.45e-05	0.000385	CcSEcCtD
Sorafenib—Headache—Betamethasone—ulcerative colitis	3.43e-05	0.000383	CcSEcCtD
Sorafenib—Headache—Dexamethasone—ulcerative colitis	3.43e-05	0.000383	CcSEcCtD
Sorafenib—Asthenia—Prednisone—ulcerative colitis	3.42e-05	0.000382	CcSEcCtD
Sorafenib—Pruritus—Prednisone—ulcerative colitis	3.37e-05	0.000377	CcSEcCtD
Sorafenib—Diarrhoea—Prednisone—ulcerative colitis	3.26e-05	0.000364	CcSEcCtD
Sorafenib—Nausea—Betamethasone—ulcerative colitis	3.25e-05	0.000363	CcSEcCtD
Sorafenib—Nausea—Dexamethasone—ulcerative colitis	3.25e-05	0.000363	CcSEcCtD
Sorafenib—Dizziness—Prednisone—ulcerative colitis	3.15e-05	0.000352	CcSEcCtD
Sorafenib—Vomiting—Prednisone—ulcerative colitis	3.03e-05	0.000338	CcSEcCtD
Sorafenib—Rash—Prednisone—ulcerative colitis	3.01e-05	0.000336	CcSEcCtD
Sorafenib—Dermatitis—Prednisone—ulcerative colitis	3e-05	0.000335	CcSEcCtD
Sorafenib—Headache—Prednisone—ulcerative colitis	2.99e-05	0.000333	CcSEcCtD
Sorafenib—Nausea—Prednisone—ulcerative colitis	2.83e-05	0.000316	CcSEcCtD
Sorafenib—RAF1—Immune System—IFNG—ulcerative colitis	2.85e-06	2.94e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—STAT3—ulcerative colitis	2.85e-06	2.94e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL2—ulcerative colitis	2.84e-06	2.94e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—PTGS2—ulcerative colitis	2.83e-06	2.92e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—RELA—ulcerative colitis	2.82e-06	2.91e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—STAT3—ulcerative colitis	2.81e-06	2.9e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—STAT3—ulcerative colitis	2.81e-06	2.9e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL2—ulcerative colitis	2.78e-06	2.87e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL2—ulcerative colitis	2.77e-06	2.86e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PPARG—ulcerative colitis	2.76e-06	2.85e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PPARG—ulcerative colitis	2.76e-06	2.85e-05	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—CXCL8—ulcerative colitis	2.76e-06	2.85e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CD4—ulcerative colitis	2.76e-06	2.84e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—JAK2—ulcerative colitis	2.75e-06	2.83e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—IL6—ulcerative colitis	2.75e-06	2.83e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—JAK2—ulcerative colitis	2.74e-06	2.83e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—IL6—ulcerative colitis	2.73e-06	2.82e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—JAK2—ulcerative colitis	2.72e-06	2.8e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—MMP9—ulcerative colitis	2.7e-06	2.79e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CALM3—ulcerative colitis	2.69e-06	2.78e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—TP53—ulcerative colitis	2.68e-06	2.77e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—JAK2—ulcerative colitis	2.68e-06	2.77e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—NFKB1—ulcerative colitis	2.67e-06	2.76e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTGS1—ulcerative colitis	2.67e-06	2.75e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—STAT3—ulcerative colitis	2.66e-06	2.75e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—NFKB1—ulcerative colitis	2.66e-06	2.75e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—ulcerative colitis	2.66e-06	2.74e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—STAT3—ulcerative colitis	2.66e-06	2.74e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—RELA—ulcerative colitis	2.66e-06	2.74e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—TGFB1—ulcerative colitis	2.64e-06	2.72e-05	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—IL2—ulcerative colitis	2.64e-06	2.72e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—MMP9—ulcerative colitis	2.63e-06	2.72e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—RELA—ulcerative colitis	2.63e-06	2.71e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—ulcerative colitis	2.62e-06	2.71e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—NFKB1—ulcerative colitis	2.6e-06	2.69e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTGS1—ulcerative colitis	2.6e-06	2.69e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—ADCY5—ulcerative colitis	2.6e-06	2.69e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—STAT3—ulcerative colitis	2.59e-06	2.67e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—ulcerative colitis	2.57e-06	2.65e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—IL6—ulcerative colitis	2.56e-06	2.64e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL1B—ulcerative colitis	2.54e-06	2.63e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—CD4—ulcerative colitis	2.54e-06	2.63e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL2—ulcerative colitis	2.54e-06	2.62e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—PTGS2—ulcerative colitis	2.53e-06	2.61e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—CXCL8—ulcerative colitis	2.51e-06	2.59e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CXCL8—ulcerative colitis	2.5e-06	2.58e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—ALB—ulcerative colitis	2.49e-06	2.56e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—ALB—ulcerative colitis	2.49e-06	2.56e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CXCL8—ulcerative colitis	2.48e-06	2.56e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—JAK2—ulcerative colitis	2.47e-06	2.55e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—JAK2—ulcerative colitis	2.47e-06	2.55e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ABCB1—ulcerative colitis	2.47e-06	2.55e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—STAT3—ulcerative colitis	2.46e-06	2.54e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—IL6—ulcerative colitis	2.46e-06	2.54e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—STAT3—ulcerative colitis	2.45e-06	2.53e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTGS1—ulcerative colitis	2.45e-06	2.53e-05	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—ALB—ulcerative colitis	2.43e-06	2.51e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTGS1—ulcerative colitis	2.43e-06	2.51e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ABCB1—ulcerative colitis	2.42e-06	2.49e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—TGFB1—ulcerative colitis	2.4e-06	2.48e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—STAT3—ulcerative colitis	2.4e-06	2.48e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CALM3—ulcerative colitis	2.4e-06	2.48e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL2—ulcerative colitis	2.4e-06	2.47e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—RELA—ulcerative colitis	2.39e-06	2.47e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—RELA—ulcerative colitis	2.39e-06	2.47e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—STAT3—ulcerative colitis	2.39e-06	2.47e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL2—ulcerative colitis	2.39e-06	2.47e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—ulcerative colitis	2.39e-06	2.47e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—NFKB1—ulcerative colitis	2.37e-06	2.45e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL2—ulcerative colitis	2.37e-06	2.45e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—JAK2—ulcerative colitis	2.35e-06	2.42e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PPARG—ulcerative colitis	2.35e-06	2.42e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CALM3—ulcerative colitis	2.34e-06	2.42e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—JAK2—ulcerative colitis	2.34e-06	2.42e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—STAT3—ulcerative colitis	2.34e-06	2.42e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PPARG—ulcerative colitis	2.32e-06	2.4e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ADCY5—ulcerative colitis	2.3e-06	2.38e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—ulcerative colitis	2.29e-06	2.37e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—TGFB1—ulcerative colitis	2.28e-06	2.35e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—TGFB1—ulcerative colitis	2.27e-06	2.35e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—ulcerative colitis	2.27e-06	2.35e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—RELA—ulcerative colitis	2.27e-06	2.35e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—RELA—ulcerative colitis	2.27e-06	2.34e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MMP9—ulcerative colitis	2.26e-06	2.34e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CXCL8—ulcerative colitis	2.26e-06	2.33e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CXCL8—ulcerative colitis	2.26e-06	2.33e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ADCY5—ulcerative colitis	2.25e-06	2.33e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MMP9—ulcerative colitis	2.24e-06	2.31e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—NFKB1—ulcerative colitis	2.24e-06	2.31e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TGFB1—ulcerative colitis	2.23e-06	2.3e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—NFKB1—ulcerative colitis	2.22e-06	2.29e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—STAT3—ulcerative colitis	2.21e-06	2.28e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CALM3—ulcerative colitis	2.21e-06	2.28e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CALM3—ulcerative colitis	2.19e-06	2.26e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IL6—ulcerative colitis	2.17e-06	2.24e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PTGS2—ulcerative colitis	2.17e-06	2.24e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PTGS2—ulcerative colitis	2.17e-06	2.24e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TGFB1—ulcerative colitis	2.17e-06	2.24e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL2—ulcerative colitis	2.16e-06	2.23e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL2—ulcerative colitis	2.16e-06	2.23e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CXCL8—ulcerative colitis	2.14e-06	2.21e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CXCL8—ulcerative colitis	2.14e-06	2.2e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—STAT3—ulcerative colitis	2.13e-06	2.2e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—ALB—ulcerative colitis	2.11e-06	2.18e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—JAK2—ulcerative colitis	2.11e-06	2.18e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—ulcerative colitis	2.09e-06	2.16e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ABCB1—ulcerative colitis	2.09e-06	2.16e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—ALB—ulcerative colitis	2.09e-06	2.16e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTGS1—ulcerative colitis	2.08e-06	2.14e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—TGFB1—ulcerative colitis	2.05e-06	2.11e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL2—ulcerative colitis	2.05e-06	2.11e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—ulcerative colitis	2.04e-06	2.11e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—RELA—ulcerative colitis	2.04e-06	2.11e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL2—ulcerative colitis	2.04e-06	2.11e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MMP9—ulcerative colitis	2.04e-06	2.11e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MMP9—ulcerative colitis	2.04e-06	2.11e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—NFKB1—ulcerative colitis	2.02e-06	2.08e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—NFKB1—ulcerative colitis	2.02e-06	2.08e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—STAT3—ulcerative colitis	2.01e-06	2.08e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—JAK2—ulcerative colitis	2.01e-06	2.08e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—STAT3—ulcerative colitis	1.99e-06	2.06e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—IL6—ulcerative colitis	1.99e-06	2.05e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—STAT3—ulcerative colitis	1.97e-06	2.03e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—IL6—ulcerative colitis	1.96e-06	2.02e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IL6—ulcerative colitis	1.96e-06	2.02e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ADCY5—ulcerative colitis	1.95e-06	2.01e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—RELA—ulcerative colitis	1.95e-06	2.01e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MMP9—ulcerative colitis	1.94e-06	2e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MMP9—ulcerative colitis	1.93e-06	1.99e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CXCL8—ulcerative colitis	1.92e-06	1.99e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—NFKB1—ulcerative colitis	1.92e-06	1.98e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—NFKB1—ulcerative colitis	1.91e-06	1.97e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—JAK2—ulcerative colitis	1.88e-06	1.94e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CALM3—ulcerative colitis	1.87e-06	1.93e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ABCB1—ulcerative colitis	1.87e-06	1.93e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TGFB1—ulcerative colitis	1.87e-06	1.93e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL6—ulcerative colitis	1.86e-06	1.92e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL6—ulcerative colitis	1.86e-06	1.92e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TGFB1—ulcerative colitis	1.85e-06	1.91e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PTGS2—ulcerative colitis	1.84e-06	1.9e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL2—ulcerative colitis	1.84e-06	1.9e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CXCL8—ulcerative colitis	1.84e-06	1.89e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TP53—ulcerative colitis	1.83e-06	1.89e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PTGS2—ulcerative colitis	1.83e-06	1.89e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—TGFB1—ulcerative colitis	1.83e-06	1.88e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—RELA—ulcerative colitis	1.82e-06	1.88e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—STAT3—ulcerative colitis	1.81e-06	1.87e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—STAT3—ulcerative colitis	1.81e-06	1.87e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—IL6—ulcerative colitis	1.81e-06	1.87e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—ulcerative colitis	1.79e-06	1.85e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TP53—ulcerative colitis	1.79e-06	1.84e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL2—ulcerative colitis	1.75e-06	1.81e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—IL6—ulcerative colitis	1.75e-06	1.8e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ADCY5—ulcerative colitis	1.74e-06	1.8e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MMP9—ulcerative colitis	1.74e-06	1.8e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—STAT3—ulcerative colitis	1.72e-06	1.78e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NFKB1—ulcerative colitis	1.72e-06	1.78e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PPARG—ulcerative colitis	1.72e-06	1.77e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—IL6—ulcerative colitis	1.72e-06	1.77e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—STAT3—ulcerative colitis	1.72e-06	1.77e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ABCB1—ulcerative colitis	1.72e-06	1.77e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CXCL8—ulcerative colitis	1.72e-06	1.77e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—IL6—ulcerative colitis	1.71e-06	1.77e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ABCB1—ulcerative colitis	1.7e-06	1.76e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ADCY5—ulcerative colitis	1.7e-06	1.75e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TGFB1—ulcerative colitis	1.68e-06	1.74e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TGFB1—ulcerative colitis	1.68e-06	1.74e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PPARG—ulcerative colitis	1.68e-06	1.73e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL6—ulcerative colitis	1.68e-06	1.73e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL6—ulcerative colitis	1.67e-06	1.73e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MMP9—ulcerative colitis	1.66e-06	1.71e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NFKB1—ulcerative colitis	1.64e-06	1.69e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL2—ulcerative colitis	1.64e-06	1.69e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL6—ulcerative colitis	1.63e-06	1.69e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL6—ulcerative colitis	1.63e-06	1.68e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—JAK2—ulcerative colitis	1.62e-06	1.67e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTGS1—ulcerative colitis	1.6e-06	1.65e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ADCY5—ulcerative colitis	1.6e-06	1.65e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TGFB1—ulcerative colitis	1.6e-06	1.65e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TGFB1—ulcerative colitis	1.59e-06	1.64e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ADCY5—ulcerative colitis	1.59e-06	1.64e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—RELA—ulcerative colitis	1.57e-06	1.62e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MMP9—ulcerative colitis	1.55e-06	1.6e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—STAT3—ulcerative colitis	1.55e-06	1.6e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ALB—ulcerative colitis	1.55e-06	1.6e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—IL6—ulcerative colitis	1.54e-06	1.59e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—ulcerative colitis	1.54e-06	1.58e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NFKB1—ulcerative colitis	1.53e-06	1.58e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—ulcerative colitis	1.52e-06	1.57e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ALB—ulcerative colitis	1.51e-06	1.56e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL6—ulcerative colitis	1.49e-06	1.54e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CXCL8—ulcerative colitis	1.48e-06	1.53e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—STAT3—ulcerative colitis	1.48e-06	1.52e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PPARG—ulcerative colitis	1.46e-06	1.5e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ABCB1—ulcerative colitis	1.45e-06	1.5e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CALM3—ulcerative colitis	1.44e-06	1.49e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TGFB1—ulcerative colitis	1.43e-06	1.48e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL2—ulcerative colitis	1.41e-06	1.46e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL6—ulcerative colitis	1.41e-06	1.45e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL6—ulcerative colitis	1.41e-06	1.45e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL6—ulcerative colitis	1.39e-06	1.44e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—ulcerative colitis	1.38e-06	1.43e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—ulcerative colitis	1.38e-06	1.43e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—STAT3—ulcerative colitis	1.38e-06	1.42e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—IL6—ulcerative colitis	1.38e-06	1.42e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TGFB1—ulcerative colitis	1.37e-06	1.41e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ADCY5—ulcerative colitis	1.36e-06	1.4e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTGS2—ulcerative colitis	1.35e-06	1.4e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MMP9—ulcerative colitis	1.34e-06	1.38e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NFKB1—ulcerative colitis	1.32e-06	1.37e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTGS2—ulcerative colitis	1.32e-06	1.36e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—ulcerative colitis	1.31e-06	1.36e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—ulcerative colitis	1.31e-06	1.35e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ALB—ulcerative colitis	1.31e-06	1.35e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PPARG—ulcerative colitis	1.3e-06	1.34e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TGFB1—ulcerative colitis	1.28e-06	1.32e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PPARG—ulcerative colitis	1.27e-06	1.31e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL6—ulcerative colitis	1.27e-06	1.31e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL6—ulcerative colitis	1.27e-06	1.31e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL6—ulcerative colitis	1.2e-06	1.24e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL6—ulcerative colitis	1.2e-06	1.24e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PPARG—ulcerative colitis	1.19e-06	1.23e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—STAT3—ulcerative colitis	1.19e-06	1.23e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PPARG—ulcerative colitis	1.18e-06	1.22e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—ulcerative colitis	1.18e-06	1.22e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ALB—ulcerative colitis	1.17e-06	1.21e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTGS2—ulcerative colitis	1.14e-06	1.18e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ALB—ulcerative colitis	1.14e-06	1.18e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—ulcerative colitis	1.13e-06	1.16e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ABCB1—ulcerative colitis	1.12e-06	1.16e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TGFB1—ulcerative colitis	1.1e-06	1.14e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL6—ulcerative colitis	1.08e-06	1.12e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ALB—ulcerative colitis	1.07e-06	1.11e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ALB—ulcerative colitis	1.07e-06	1.1e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—ulcerative colitis	1.05e-06	1.09e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ADCY5—ulcerative colitis	1.05e-06	1.08e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL6—ulcerative colitis	1.03e-06	1.06e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTGS2—ulcerative colitis	1.02e-06	1.05e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPARG—ulcerative colitis	1.01e-06	1.04e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTGS2—ulcerative colitis	9.97e-07	1.03e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL6—ulcerative colitis	9.63e-07	9.94e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTGS2—ulcerative colitis	9.4e-07	9.7e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTGS2—ulcerative colitis	9.32e-07	9.62e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ALB—ulcerative colitis	9.1e-07	9.39e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—ulcerative colitis	9.09e-07	9.38e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL6—ulcerative colitis	8.32e-07	8.58e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTGS2—ulcerative colitis	7.96e-07	8.22e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPARG—ulcerative colitis	7.81e-07	8.06e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ALB—ulcerative colitis	7.02e-07	7.25e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTGS2—ulcerative colitis	6.14e-07	6.34e-06	CbGpPWpGaD
